CN101687885B - 作为激酶抑制剂的稠合噻唑衍生物 - Google Patents

作为激酶抑制剂的稠合噻唑衍生物 Download PDF

Info

Publication number
CN101687885B
CN101687885B CN200880024430XA CN200880024430A CN101687885B CN 101687885 B CN101687885 B CN 101687885B CN 200880024430X A CN200880024430X A CN 200880024430XA CN 200880024430 A CN200880024430 A CN 200880024430A CN 101687885 B CN101687885 B CN 101687885B
Authority
CN
China
Prior art keywords
methyl
dimethyl
morpholin
thiazolo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200880024430XA
Other languages
English (en)
Chinese (zh)
Other versions
CN101687885A (zh
Inventor
R·P·亚历山大
P·S·奥吉拉
K·V·L·克雷佩
A·M·福雷
R·J·弗兰克林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0612644A external-priority patent/GB0612644D0/en
Priority claimed from GB0620062A external-priority patent/GB0620062D0/en
Application filed by UCB SA filed Critical UCB SA
Priority claimed from PCT/GB2008/002194 external-priority patent/WO2009001089A1/en
Publication of CN101687885A publication Critical patent/CN101687885A/zh
Application granted granted Critical
Publication of CN101687885B publication Critical patent/CN101687885B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200880024430XA 2006-06-26 2008-06-24 作为激酶抑制剂的稠合噻唑衍生物 Active CN101687885B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0612644A GB0612644D0 (en) 2006-06-26 2006-06-26 Therapeutic agents
GB0620062A GB0620062D0 (en) 2006-10-10 2006-10-10 Therapeutic agents
PCT/GB2007/002390 WO2008001076A1 (en) 2006-06-26 2007-06-26 Fused thiazole derivatives as kinase inhibitors
GBPCT/GB2007/002390 2007-06-26
PCT/GB2008/002194 WO2009001089A1 (en) 2007-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101687885A CN101687885A (zh) 2010-03-31
CN101687885B true CN101687885B (zh) 2012-08-22

Family

ID=38671000

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880024430XA Active CN101687885B (zh) 2006-06-26 2008-06-24 作为激酶抑制剂的稠合噻唑衍生物

Country Status (20)

Country Link
US (3) US8242116B2 (cg-RX-API-DMAC10.html)
EP (2) EP2035436B1 (cg-RX-API-DMAC10.html)
CN (1) CN101687885B (cg-RX-API-DMAC10.html)
AT (1) ATE510840T1 (cg-RX-API-DMAC10.html)
AU (1) AU2008269577B2 (cg-RX-API-DMAC10.html)
CA (1) CA2692085C (cg-RX-API-DMAC10.html)
CO (1) CO6270229A2 (cg-RX-API-DMAC10.html)
CY (1) CY1114419T1 (cg-RX-API-DMAC10.html)
DK (1) DK2170906T3 (cg-RX-API-DMAC10.html)
EA (1) EA017187B1 (cg-RX-API-DMAC10.html)
ES (2) ES2365258T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20130523T1 (cg-RX-API-DMAC10.html)
IL (1) IL202659A0 (cg-RX-API-DMAC10.html)
ME (1) ME01592B (cg-RX-API-DMAC10.html)
MX (1) MX2009013740A (cg-RX-API-DMAC10.html)
MY (1) MY148852A (cg-RX-API-DMAC10.html)
PL (1) PL2170906T3 (cg-RX-API-DMAC10.html)
PT (1) PT2170906E (cg-RX-API-DMAC10.html)
RS (1) RS52824B (cg-RX-API-DMAC10.html)
WO (1) WO2008001076A1 (cg-RX-API-DMAC10.html)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009071890A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Tricyclic kinase inhibitors
WO2009071895A1 (en) * 2007-12-04 2009-06-11 Ucb Pharma S.A. Fused thiazole and thiophene derivatives as kinase inhibitors
AU2008343932B2 (en) 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
ATE531372T1 (de) 2008-04-07 2011-11-15 Amgen Inc Gem-disubstituierte und spirocyclische aminopyridine/pyrimidine als zellcyclus- inhibitoren
JPWO2009130900A1 (ja) * 2008-04-24 2011-08-11 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US8603945B2 (en) * 2008-07-23 2013-12-10 The Regents Of The University Of California Methods and compositions for providing salicyclic acid-independent pathogen resistance in plants
EP2341052A4 (en) * 2008-09-05 2011-10-12 Shionogi & Co RING-CONDENSED MORPHOLINE DERIVATIVITY WITH PI3K-INHIBITING EFFECT
AU2010216219A1 (en) 2009-02-17 2011-09-01 Vertex Pharmaceuticals Incorporated Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase
AR076126A1 (es) * 2009-03-18 2011-05-18 Schering Corp Compuestos biciclicos como inhibidores de diacilglicerol aciltransferasa
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
ES2638323T3 (es) * 2009-05-20 2017-10-19 Glaxosmithkline Llc Derivados de tiazolopirimidinona como inhibidores de PI3 quinasa
GB0912946D0 (en) 2009-07-24 2009-09-02 Addex Pharmaceuticals Sa New compounds 5
MX2012002059A (es) 2009-08-20 2012-04-19 Karus Therapeutics Ltd Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa.
EA020010B1 (ru) * 2009-12-18 2014-07-30 Янссен Фармацевтика Нв БИЦИКЛИЧЕСКИЕ ТИАЗОЛЫ В КАЧЕСТВЕ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 РЕЦЕПТОРОВ
ES2431302T3 (es) 2009-12-18 2013-11-25 Janssen Pharmaceutica, N.V. Tiazoles bicíclicos como moduladores alostéricos de receptores mGluR5
EP2582693B1 (de) 2010-06-15 2016-03-30 Bayer Intellectual Property GmbH Neue ortho-substituierte arylamid-derivate
BR112013007056A2 (pt) 2010-10-01 2019-09-24 Basf Se compostos de imina
AU2011316016A1 (en) * 2010-10-13 2013-05-30 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
BR112013012961A2 (pt) * 2010-11-24 2019-09-24 Exelixis Inc benzoxazepinas como inhibidores de mtor e métodos de seu uso e fabricação
CN102649777B (zh) * 2011-02-25 2014-03-12 中国中化股份有限公司 一种制备1-芳基-3-羧基-5-吡唑啉酮类化合物的方法
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
JO3398B1 (ar) 2011-12-22 2019-10-20 Novartis Ag مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US20160039767A1 (en) 2013-03-14 2016-02-11 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9365527B2 (en) 2013-03-14 2016-06-14 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153208A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970220A2 (en) 2013-03-14 2016-01-20 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
BR112015022785A2 (pt) 2013-03-14 2017-07-18 Epizyme Inc composto; composição farmacêutica; kit ou artigo farmacêutico embalado; método de inibição de uma arginina metil transferase (rmt); método de modulação da expressão genética; método de modulação da transcrição; e método de tratamento de um distúrbio mediado por rmt
CA2903264A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
WO2015059049A1 (de) * 2013-10-21 2015-04-30 Umicore Ag & Co. Kg Monoarylierung aromatischer amine
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN108570043A (zh) * 2018-06-20 2018-09-25 王延娇 一种化合物及其作为选择性pi3k抑制剂在治疗肿瘤中的应用
US20220202824A1 (en) 2018-09-13 2022-06-30 Stemline Therapeutics, Inc. Methods for Treating Centronuclear Myopathy
AU2019410261B2 (en) 2018-12-19 2025-10-02 Leo Pharma A/S Amino-acid anilides as small molecule modulators of IL-17
BR112021013105A2 (pt) * 2019-01-08 2021-09-21 Kyorin Pharmaceutical Co., Ltd. Inibidor de 15-pgdh
JP7532385B2 (ja) 2019-01-31 2024-08-13 杏林製薬株式会社 １５－ｐｇｄｈ阻害薬

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114606A1 (en) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114606A1 (en) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Fused thiazole derivatives as kinase inhibitors

Also Published As

Publication number Publication date
AU2008269577B2 (en) 2012-12-20
ATE510840T1 (de) 2011-06-15
CO6270229A2 (es) 2011-04-20
EA201000038A1 (ru) 2010-06-30
US8338592B2 (en) 2012-12-25
AU2008269577A1 (en) 2008-12-31
MY148852A (en) 2013-06-14
ME01592B (me) 2014-09-20
ES2416364T3 (es) 2013-07-31
EP2170906B1 (en) 2013-04-03
US20130079330A1 (en) 2013-03-28
PL2170906T3 (pl) 2013-08-30
US8710054B2 (en) 2014-04-29
EA017187B1 (ru) 2012-10-30
EP2035436A1 (en) 2009-03-18
IL202659A0 (en) 2010-06-30
CA2692085A1 (en) 2008-12-31
ES2365258T3 (es) 2011-09-27
EP2035436B1 (en) 2011-05-25
CN101687885A (zh) 2010-03-31
PT2170906E (pt) 2013-06-25
US8242116B2 (en) 2012-08-14
US20110003785A1 (en) 2011-01-06
CA2692085C (en) 2015-10-13
DK2170906T3 (da) 2013-06-24
HRP20130523T1 (en) 2013-07-31
MX2009013740A (es) 2010-02-01
EP2170906A1 (en) 2010-04-07
CY1114419T1 (el) 2016-08-31
US20100137302A1 (en) 2010-06-03
RS52824B (cg-RX-API-DMAC10.html) 2013-10-31
WO2008001076A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
CN101687885B (zh) 作为激酶抑制剂的稠合噻唑衍生物
JP5243953B2 (ja) キナーゼ阻害剤としての縮合チアゾール誘導体
JP5249787B2 (ja) Ｍｅｋ阻害剤としてのチエノピリジン誘導体
BR112013004750B1 (pt) Derivados de quinolina e quinoxalina como inibidores da cinase
KR19990007863A (ko) 혈소판 활성 인자 길항제로서의 인돌-3-카보닐 및 인돌-3-설포닐 유도체
WO2009071888A1 (en) Pyrrolothiazoles as pi3-kinase inhibitors
US8168634B2 (en) Thiazole derivatives as kinase inhibitors
HUP0004644A2 (hu) Neutrofil elasztáz inhibitor hatású pirrolo-pirrolon-származékok és ilyen vegyületeket hatóanyagként tartalmazó gyógyszerkészítmények
KR101577314B1 (ko) 키나제 억제제로서의 접합된 티아졸 유도체
WO2011024871A1 (ja) 縮合複素環誘導体およびその用途
HK1140756B (en) Fused thiazole derivatives as kinase inhibitors
WO2010146351A1 (en) Indolylmethyl-morpholine derivatives as kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant